Similar articles

• [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].

  Von Zweigbergk M, Nordin B, Jonsson S. Von Zweigbergk M, et al. Lakartidningen. 1996 Oct 9;93(41):3573-6. Lakartidningen. 1996. PMID: 8965514 Swedish. No abstract available.
• Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.

  Ferrara P, D'Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Ferrara P, et al. BJU Int. 2001 May;87(7):674-8. doi: 10.1046/j.1464-410x.2001.02152.x. BJU Int. 2001. PMID: 11350411
• Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism.

  Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE. Buyse G, et al. J Urol. 1998 Sep;160(3 Pt 1):892-6. doi: 10.1016/S0022-5347(01)62828-3. J Urol. 1998. PMID: 9720583
• Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.

  Lose G, Nørgaard JP. Lose G, et al. BJU Int. 2001 Jun;87(9):767-73. doi: 10.1046/j.1464-410x.2001.02227.x. BJU Int. 2001. PMID: 11412211 Review. No abstract available.
• [Intravesical treatment of overactive bladder syndrome].

  Haferkamp A, Hohenfellner M. Haferkamp A, et al. Urologe A. 2006 Oct;45(10):1283-8. doi: 10.1007/s00120-006-1178-4. Urologe A. 2006. PMID: 16972089 Review. German.